In part one of this blog series, we emphasized the importance and potential impact of early outreach on partnering for early-stage biotech companies. Let’s turn our attention now to another setting where timing can favorably and significantly impact the deal process –...
For the moment, let’s put aside the en fuego (but soon to combust?) nature of the biotech IPO market and parallel frothiness (but for how long?) of orphan disease drug development. Our recent transaction efforts stimulated some thoughts on the impact of time, and more...
Geoff Meyerson spoke at and participated in the Panel Discussion, “The 2013 mHealth Prognosis: Converging Business and Legal Trends,” which was held at 100 Bodek Lounge at the University of Pennsylvania on June 26, 2013 at 5:30 pm. Locust Walk Partners, Wharton Health...
Locust Walk Partners, LLC, a transaction advisory firm that supports biopharmaceutical companies, is pleased to announce that biotech industry and venture capital veteran Chris Ehrlich has joined the firm as Managing Director. Based in San Francisco, Mr. Ehrlich will...
